Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Calithera Biosciences, Inc. CALA
$0.04
+$0.01 (20.00%)
На 18:00, 12 мая 2023
+4 900.00%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
145958.00000000
-
week52high
5.10
-
week52low
0.01
-
Revenue
0
-
P/E TTM
0
-
Beta
1.18823500
-
EPS
-7.94000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Neutral | 29 авг 2022 г. |
| SVB Leerink | Outperform | Outperform | 16 авг 2022 г. |
| Wells Fargo | Equal-Weight | Equal-Weight | 11 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 04 апр 2022 г. |
| Ladenburg Thalmann | Buy | 31 янв 2022 г. | |
| SVB Leerink | Market Perform | Outperform | 15 ноя 2022 г. |
| Ladenburg Thalmann | Neutral | Buy | 15 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| PAKIANATHAN DEEPIKA | D | 0 | 1172 | 27 янв 2023 г. |
| Molineaux Christopher | D | 27859 | 217 | 23 янв 2023 г. |
| Wong Stephanie | D | 6287 | 317 | 23 янв 2023 г. |
| Molineaux Susan | D | 27859 | 526 | 23 янв 2023 г. |
| Kuriakose Emil | D | 3539 | 79 | 23 янв 2023 г. |
| Sjogren Eric | D | 8467 | 279 | 23 янв 2023 г. |
| TAKEDA PHARMACEUTICAL CO LTD | A | 1000000 | 1000000 | 01 июл 2022 г. |
| TAKEDA PHARMACEUTICAL CO LTD | A | 0 | 1000000 | 01 июл 2022 г. |
| Orford Keith | A | 20000 | 20000 | 01 июн 2022 г. |
| Wolff Henry Ward | A | 20000 | 20000 | 01 июн 2022 г. |
Новостная лента
Calithera Biosciences, Inc. (CALA) Q3 2022 Earnings Call Transcript
Seeking Alpha
14 ноя 2022 г. в 22:17
Calithera Biosciences, Inc. (NASDAQ:CALA ) Q3 2022 Earnings Conference Call November 14, 2022 5:00 PM ET Company Participants Stephanie Wong - CFO & Secretary Susan Molineaux - Founder, CEO, President & Director Emil Kuriakose - Chief Medical Officer Conference Call Participants Jiale Song - Jefferies Swayampakula Ramakanth - H.C. Wainwright & Co. Matthew Cowper - SVB Securities Aydin Huseynov - Ladenburg Thalmann Operator Good day, ladies and gentlemen, and thank you for standing by.
Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
GlobeNewsWire
08 ноя 2022 г. в 16:30
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company's third quarter 2022 financial results will be released on Monday, November 14, 2022. Company management will host a conference call on Monday, November 14, 2022, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
Calithera's stock is up 14% after announcing Fast Track designation for lung-cancer drug candidate
Market Watch
03 окт 2022 г. в 09:08
Shares of Calithera Biosciences Inc. CALA, -0.68% jumped 14.6% in premarket trading on Monday after the company said it received a Fast Track designation for its experimental treatment for non-small cell lung cancer. The drug is currently being tested in Phase 2 clinical trial.
3 Penny Stocks With Surprisingly Superior Fundamentals
InvestorPlace
09 сент 2022 г. в 15:14
The question of when to add risk to a portfolio is a difficult one to answer. A rush toward riskier equities after the pandemic-induced sell-off led to a surge in many stocks.
Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
06 сент 2022 г. в 16:05
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company's founder, president and chief executive officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12-14 both virtually and in New York, NY.